NEW YORK, Oct. 16 – German biotech company atugen and AstraZeneca plan to use atugen’s GeneBloc technology to enhance target validation and drug development in an undisclosed number of “major disease areas” of interest to AstraZeneca.

Terms of the deal call for Berlin-based atugen to retain all rights to specific GeneBlocs it develops for the drugs giant and will have an option to license certain intellectual property generated in the collaboration, according to a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.